ClearPoint Neuro Inc 2026年季度报告

FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedMarch 31, 2026 Or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____to _____ Commission file number:001-34822 ClearPoint Neuro, Inc.(Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction(IRS Employerof Incorporation or Organization)Identification Number) 120 S. Sierra Ave., Suite 100Solana Beach, California92075(Address of Principal Executive Offices)(Zip Code) (888) 287-9109(Registrant’s Telephone Number, Including Area Code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files.)YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting companyEmerging growth company Large accelerated filerNon-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YesNo As of May 7, 2026, there were 29,989,563 shares of common stock outstanding. CLEARPOINT NEURO, INC. TABLE OF CONTENTS PART I – FINANCIAL INFORMATION Item 1.Financial Statements (unaudited)1Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20251Condensed Consolidated Statements of Operations for the three months endedMarch 31, 2026 and 20252Condensed Consolidated Statements of Stockholders’ Equity for the three months endedMarch 31, 2026and 20253Condensed Consolidated Statements of Cash Flows for the three months endedMarch 31, 2026 and 20254Notes to Condensed Consolidated Financial Statements6Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations22Item 3.Quantitative and Qualitative Disclosures About Market Risk29Item 4.Controls and Procedures29 Item 1.Legal Proceedings29Item 1A.Risk Factors29Item 2.Unregistered Sales of Equity Securities and Use of Proceeds30Item 3.Defaults Upon Senior Securities30Item 4.Mine Safety Disclosures30Item 5.Other Information30Item 6.Exhibits31 Trademarks, Trade Names and Service Marks ClearPoint Neuro®,ClearPoint®,SmartFlow®, SmartFrame®, SmartGrid®, Inflexion®,ClearPoint Maestro®,SmartFrameArray®,SmartFrame OR®,ClearPoint Neuro Orchestra®, ClearPoint Prism®, ClearPointer®,When Your Path is Unclear, We PointThe Way®,ClearPoint Advanced Laboratories™, IRRAS®, and IRRAFLOW®are all trademarks of ClearPoint Neuro, Inc. and itsaffiliates. Any other trademarks, trade names or service marks referred to in this Quarterly Report on Form 10-Q (this “QuarterlyReport”) are the property of their respective owners. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains “forward-looking statements” as defined under the U.S. federal securities laws. Allstatements, other than statements of historical fact, in this Quarterly Report, including statements relating to our expectations forperformance, revenues and costs, and the adequacy of cash and cash equivalent balances to support operations and meet futureobligations, are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and otherfactors that may cause our actual results, performance or achievements to be materially different from any future results, performanceor achievements, expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,”“intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” and similar expressions intended to identifyforward-looking statements, although not all forward-looking statement